Lexicon Pharmaceuticals
LXRX· Manufacturing· Fiscal year ends in December
Michael S. Exton, Ph.D. is the CEO of Lexicon Pharmaceuticals and was paid $3.6M in FY2025 (Dec), up 25%.
Executives1
See all- 1Michael S. Exton, Ph.D.Chief Executive Officer and DirectorFY2025
Named executives and their total pay, from the Summary Compensation Table of the latest proxy.
Pay
See allLexicon Pharmaceuticals paid CEO Michael S. Exton, Ph.D. $3.6M in FY2025 (Dec). No other named executive of that year is on file.
| Name | |||
|---|---|---|---|
| Michael S. Exton, Ph.D.Chief Executive Officer and Director | Not disclosed |
of each named executive, from the Summary Compensation Table of each proxy.
Peers14
See allThe FY2023 (Dec) proxy of Lexicon Pharmaceuticals names 14 peer companies for pay. Among Lexicon Pharmaceuticals and these peers, CEO pay was the lowest of 3 and total shareholder return was 2nd highest of 3.
3rd highest of 3in Lexicon Pharmaceuticals and its pay peers, FY2023 (Dec) by CEO pay:
2nd highest of 3in Lexicon Pharmaceuticals and its pay peers, FY2023 (Dec) by total shareholder return:
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year.
Board5
See all- Raymond DebbaneChair · 18 yr on the boardIndependentCorporate Governance (Chair)—Paid as an executive
- Christopher J. SobeckiDirector · 18 yr on the boardIndependent—Paid as an executive
- Judith L. Swain, M.D.Director · 18 yr on the boardIndependentCompensation, Corporate Governance—Paid as an executive
- Philippe J. AmouyalDirector · 18 yr on the boardIndependentCompensation (Chair)—Paid as an executive
- Michael S. Exton, Ph.D.Director · 1 yr on the boardNot independent—Paid as an executive
The board of the latest proxy (FY2025).
Activity
Filings6
See all| Proxy statement | DEF 14A | Mar 16, 2026 | FY2025 |
| Annual report | 10-K | Mar 5, 2026 | FY2025 |
| Proxy statement | DEF 14A | Apr 22, 2025 | FY2024 |
| Annual report | 10-K | Mar 7, 2025 | FY2024 |
| Proxy statement | DEF 14A | Mar 26, 2024 | FY2023 |
| Annual report | 10-K | Mar 25, 2024 | FY2023 |
